|Bid||1.7900 x 2900|
|Ask||1.8300 x 4000|
|Day's Range||1.7200 - 1.8600|
|52 Week Range||0.7400 - 9.7500|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...
The Chester County biopharmaceuticals sold its Rhofade cream as part of its plan to focus it resources on developing products immuno-inflammatory diseases.
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks ...
Anyone researching Aclaris Therapeutics, Inc. (NASDAQ:ACRS) might want to consider the historical volatility of the...
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Aclaris Therapeutics (NASDAQ: ACRS ) shares ...
Aclaris, a biopharma company focusing on immune-inflammatory and dermatological diseases, announced positive results from a Phase 3 THWART-2 study that is evaluating the A-101 45% topical solution as an investigational new drug for the treatment of common warts. A-101 is a proprietary high-concentration hydrogen peroxide topical solution. The THWART-2 trial studied 502 subjects with one to six warts at the baseline who were randomized and self-administered either A-101 or a placebo twice a week over eight weeks.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder ...
Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aclaris (ACRS) delivered earnings and revenue surprises of 6.49% and 1.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...